Clinical effect of sacubitril valsartan in treatment of heart failure patients with low systolic blood pressure

  AIM  To explore the clinical effects of sacubitril valsartan on heat failure with low systolic blood pressure.

  METHODS  One hundred and sixteen heart failure patients with low systolic blood pressure (90~100) mmHg treated in our Department from December 2018 to December 2019 were randomly divided into a control group and a research group. Based on general treatment, the control group was given an initial dose at 20mg valsartan once a day, while the research group was given an initial dose at 25mg sacubitril valsartan twice a day.

  RESULTS   After 6 months of treatment, sacubitril valsartan significantly improved the heart function grade of NYHA, left ventricular ejection fraction (LVEF), NT-proBNP, 6 min walking distance (6MWD) and the Minnesota heart failure scale score (MHFQL) compared with those before treatment (P<0.05), and the improvement in the research group was better than that in the control group. There was no significant difference in the incidence of cardiovascular events and drug related events between the two groups.

  CONCLUSION  The effect of sacubitril valsartan is more significant than valsartan in heart failure patients with low systolic blood pressure (90~100mmHg), which is worthy of additional research and clinical consideration.